Neutralisation sensitivity of the SARS-CoV-2 omicron BA. 2.75 sublineage
6 Sheward DJ, Kim C, Fischbach J, et al. Evasion of neutralising antibodies by omicron
sublineage BA. 2.75. Lancet Infect Dis 2022; published online Sept 1. https://doi …
sublineage BA. 2.75. Lancet Infect Dis 2022; published online Sept 1. https://doi …
Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
CD19 chimeric antigen receptor (CAR) T cells can induce prolonged remissions and
potentially cure a significant proportion of patients with relapsed/refractory large B-cell …
potentially cure a significant proportion of patients with relapsed/refractory large B-cell …
Development of therapeutic antibodies for the treatment of diseases
Z Wang, G Wang, H Lu, H Li, M Tang, A Tong - Molecular biomedicine, 2022 - Springer
Since the first monoclonal antibody drug, muromonab-CD3, was approved for marketing in
1986, 165 antibody drugs have been approved or are under regulatory review worldwide …
1986, 165 antibody drugs have been approved or are under regulatory review worldwide …
[HTML][HTML] Broadly neutralizing antibodies against COVID-19
The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …
Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of
the devastating global COVID-19 pandemic announced by WHO in March 2020. Through …
the devastating global COVID-19 pandemic announced by WHO in March 2020. Through …
SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis
Z Raglow, D Surie, JD Chappell, Y Zhu… - The Lancet …, 2024 - thelancet.com
Summary Background Prolonged SARS-CoV-2 infections in people who are
immunocompromised might predict or source the emergence of highly mutated variants. The …
immunocompromised might predict or source the emergence of highly mutated variants. The …
Current effective therapeutics in management of COVID-19
K Atluri, I Aimlin, S Arora - Journal of Clinical Medicine, 2022 - mdpi.com
The current pandemic due to the SARS-CoV-2 virus has caused irreparable damage
globally. High importance is placed on defining current therapeutics for Coronavirus …
globally. High importance is placed on defining current therapeutics for Coronavirus …
A high-level programming language for generative protein design
Combining a basic set of building blocks into more complex forms is a universal design
principle. Most protein designs have proceeded from a manual bottom-up approach using …
principle. Most protein designs have proceeded from a manual bottom-up approach using …
A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
Z Jia, K Wang, M Xie, J Wu, Y Hu, Y Zhou… - Protein & …, 2024 - academic.oup.com
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) has lasted for more than four years …
respiratory syndrome coronavirus-2 (SARS-CoV-2) has lasted for more than four years …
Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …